Zhejiang Haizheng Pharmaceutical Co., Ltd. announced that as of April 15, 2024, the company will trigger a downward revision of the “Haizheng Transfer” share conversion price. After deliberation and approval at the 26th meeting of the 9th board of directors of the company, the board of directors of the company decided not to exercise the right to revise the “Haizheng Transfer” share conversion price downward, and that within the next 12 months (April 16, 2024 to April 15, 2025), if once again triggering the terms of downward revision of the conversion price of convertible corporate bonds (hereinafter referred to as “convertible bonds”), it will not propose a downward correction plan.
海正药业：不向下修正“海正定转”转股价格
Haizheng Pharmaceutical: No downward revisions to the “Haizheng Dingzheng Transfer” share conversion price
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.